Overview

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employs technologies, such as its ArQule Kinase Inhibitor Platform to design and develop drugs. Its product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase (c-Met). C-Met is a target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. It has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo in the United States, Europe, South America and the rest of the world, excluding Japan and other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. In August 2011, Kyowa Hakko Kirin announced the initiation of the Phase III ATTENTION (Asian Trial of Tivantinib plus Erlotinib vs. Erlotinib for NSCLC without EGFR Mutation) trial of tivantinib in combination with erlotinib.

Endorsements